Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients with Refractory Solid Tumors

Trial Status: complete

This phase I trial studies the side effects and best dose of 5-fluoro-2'-deoxycytidine when given together with tetrahydrouridine in treating patients with solid tumors that has not responded to previous treatment (refractory). 5-fluoro-2'-deoxycytidine may work by changing how genes work in tumor cells and tetrahydrouridine may help keep 5-fluoro-2'-deoxycytidine from being broken down in the body.